BACKGROUND: Molecular characterization of circulating tumor cells (CTCs) holds great promise for monitoring metastatic progression and characterizing metastatic disease. However, leukocyte and red blood cell contamination of routinely isolated CTCs makes CTC-specific molecular characterization extremely challenging.
demonstrate a hitherto unreported utility of the FTA Elute Card in miRNA extraction, and show how the FTA Elute Card can be used for highly sensitive detection of rare cells existing in the complex blood mixture.
Materials and Methods

CELL CULTURE
Human MCF7 breast, HT29 colon, and DU145 prostate cancer cell lines were cultured in the 5% CO 2 humidified incubator at 37°C using MEM (minimum essential medium; ATCC), DMEM (Sigma), and RPMI (Sigma), respectively, and supplemented with 10% FBS (Thermo Fisher Scientific). Cells were lysed using either the FTA Elute Card (GE Healthcare Life Sciences), or by addition of Cell-to-CT TM lysis solution (Thermo Fisher Scientific), according to the manufacturers' instructions.
PATIENTS AND HEALTHY VOLUNTEERS
Peripheral blood samples were collected in spray-coated K 2-EDTA Vacutainer Tubes [Becton Dickinson (BD)] from healthy volunteers and patients with breast or colorectal cancer (see Table 1 in the Data Supplement that accompanies the online version of this article at http:// www.clinchem.org/content/vol63/issue3). The blood samples were collected by phlebotomists of the National University Hospital-National University of Singapore Tissue Repository (TR NUH-NUS) and the NUH Blood Donation Center, and the oncologists at Tucker Medical Private Limited (Singapore), after prior counseling and written informed consent. Both sampling and study protocols were approved by the Institutional Review Board committee of the NUS.
PLASMA COLLECTION
Venous blood samples (3 mL) were collected into K 2 -EDTA Vacutainers (BD) and diluted 1:1 with PBS containing 5 g/L BSA and 2 mmol/L K 2 -EDTA. The diluted plasma was centrifuged at 3000g at room temperature for 10 min. Total nucleic acids were extracted from plasma by spotting 5-30 L of diluted plasma onto a 5.5 mm ϫ 11 mm FTA Elute Micro Card (cat. no.: WB120401, GE Healthcare Life Sciences). Unused plasma aliquots were stored at Ϫ80°C.
CTC ISOLATION
A separate 15-mL venous blood sample was collected from the same patient, into K 2 EDTA tube (BD). The blood was diluted 1:1 with PBS/5 g/L BSA/2 mmol/L EDTA and the diluted blood was filtered using a 40-m cell strainer (BD) directly into the funnel filtration system (CellSievo) and filtered through the microsieve at a flow rate of 500 L of blood per minute, as described previously (18 ) . Four 1-mL washes with PBS/5 g/L BSA/2 mmol/L EDTA were performed, followed by a 30-min incubation with a 100-L antibody mixture containing 20 L 100 g/L 4Ј,6-diamidino-2-phenylindole (DAPI; Thermo Fisher Scientific), 20 L AlexaFluor-488 conjugated anti-CD45 antibody (AbD Serotec), 20 L phycoerythrin-conjugated anti-EpCAM (epithelial cell adhesion molecule) (BioLegend), and 20 L PBS buffer. This was followed by 4 1-mL washes with EDTAfree PBS/5 g/L BSA. CTCs were eluted in 500 L PBS/5 g/L BSA from the microsieve by reversing the flow of the pump and collected in sterile 1.5-mL tubes. The eluate containing a mixture of RBCs, WBCs, and CTCs was centrifuged at 600g for 5 min (min). Most of the supernatant was removed. The cell pellet was resuspended in 5 L PBS/5 g/L BSA.
PARTITIONING OF CTCs
The eluate was spotted onto the wells of a MicroWell TM Minitray (Nunc) with 0.5 L in each well. Each well was examined under BX61 fluorescence microscope (Olympus). WBCs fluoresced blue (DAPI) and green (AlexaFluor-488 conjugated anti/CD45) (see online Supplemental Fig. 1 ). The MetaMorph software (Molecular Devices) was used to acquire images with each of the 3 filter sets (U-MNUA2 for DAPI, U-MNIBA3 for the green probes, and U-MNIGA3 for the red probes), and to control the motorized xy-stage when the entire microsieve area was scanned. CTC-containing wells were then pooled together for miRNA extraction using the FTA Elute Card, along with an equal number of CTC-null wells to serve as background control.
FTA EXTRACTION AND PURIFICATION OF miRNAs FROM CTCs
AND PLASMA
For plasma, samples were directly applied onto the FTA Elute Micro Card (GE Healthcare Life Sciences) and allowed to dry at room temperature for an hour. For CTC preparation, a small piece of The FTA Elute paper (5 mm ϫ 5 mm) was pressed against the bottom of the microwell with moderate force for 5 s to soak up and lyse the cells (see online Supplemental Fig. 2 ). The discs were transferred to fresh 1.5-mL Eppendorf tubes and washed in 500 L 70% ethanol for 5 min before drying. The dried discs were soaked in 12-20 L of diethyl pyrocarbonate (DEPC)-treated water. miRNAs were eluted at 95°C for 30 min. During the process, different forceps were used to handle the CTC-containing and CTC-null samples respectively to avoid cross-contamination.
REVERSE TRANSCRIPTION AND REAL-TIME qPCR
Thirty miRNAs were analyzed in both plasma and CTC samples. These were selected based on miRNA expression profiling in breast cancer vs healthy tissues and literature search for their roles in breast cancer. RT-qPCR analysis of miRNA expression was performed using IDEAL miRNA assays (MiRXES, Singapore) (19 ) . Multiplex reverse transcription was carried out in 3.75 L reaction volume containing 100 nmol/L stem-loop primers, 1.3 mmol/L dNTPs (Thermo Fisher Scientific), 1ϫ reverse transcription buffer (Thermo Fisher Scientific), 1.07 U RNase Inhibitor (Thermo Fisher Scientific), 1ϫ Superscript VILO enzyme (Thermo Fisher Scientific), and 2 L total miRNAs extracted using the FTA Elute Card as described above. The reaction was conducted at 42°C for an hour using a thermal cycler (Eppendorf). qPCR was performed on the 7900HT real-time PCR instrument (Thermo Fisher Scientific) using SYBR Green I. Thermocycling of cDNAs was performed with 10 min of initial denaturation at 95°C, followed by 40 cycles of 30 s denaturation at 95°C and 30 s annealing/ extension at 60°C. 1.6 L of each 1:10 diluted cDNA sample was subjected to qPCR in a total volume of 8 L in 1ϫ IDEAL miRNA qPCR Master Mix with 1ϫ miRNA-specific qPCR assay (MiRXES, Singapore). Raw threshold cycle (C q ) values were calculated using the 7500 software v2.0.5 (Thermo Fisher Scientific) with automatic baseline and threshold settings. Each cDNA sample was run in duplicates for the qPCR stage-should C q values between duplicates differ by Ͼ1.0 for either CTC-containing or CTC-negative wells, the miRNA (e.g., miR-125b) under investigation for the particular time-point/patient will be rejected and marked as "data unavailable." Reverse-transcription qPCR (RT-qPCR) for cancer patients was performed alongside that of at least 1 healthy donor at all times.
REAL-TIME RT-qPCR ARRAY
An ABI RT-qPCR array (Card A, Life Technologies) was performed for profiling of expression levels of 381 miRNAs using patient CTC samples. Briefly, cDNA synthesis was performed with 7.5 L reagent including 1ϫ stem-loop reverse transcription Human primers at 10 mmol/L, 2.67 mmol/L dNTPs (Thermo Fisher Scientific), 1ϫ reverse transcription buffer (Thermo Fisher Scientific), 3 mmol/L MgCl 2 , 1.07 U RNase Inhibitor (Thermo Fisher Scientific), 1ϫ Superscript VILO enzyme (Thermo Fisher Scientific), and 4 L total RNA. The 7.5 L reactions were incubated at 42°C for an hour in a thermal cycler (Eppendorf). The cDNA product (7.5 L) was mixed with 892.5 L of 1ϫ TaqMan® Universal PCR Master Mix (Life Technologies), loaded into the ABI miRNA TaqMan array card and spun down twice at 250g for 1 min before sealing. Real-time cDNA amplification was then performed at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min, using the ViiA7 real-time PCR system (Life Technologies).
CALCULATION OF ΔC q , FOLD DIFFERENCES AND THRESHOLD
Mean C q values were normalized to all miRNAs detected, as previously described (20 ) . The difference in C q values was calculated for the 2 fractions (⌬C q ϭ C q of CTC-containing wells -C q of CTC-null wells). Fold difference was obtained (2 ⌬Cq ) and this value indicates the extent of miRNA expression due to CTCs only. ⌬C q values for all miRNAs assayed for cancer patients and healthy controls were presented as a dot plot.
DATA ANALYSIS
Mean C q values were normalized to all miRNAs detected from eluate extracted from the plasma. Using the normalized C q values, a heat map was generated and standard hierarchical clustering was executed with Euclidean distance metric. All analyses were performed using the DataAssist Software (Thermo Fisher Scientific). Principal component analysis (PCA) was performed using XLSTAT.
STATISTICAL ANALYSIS
The line of best fit was generated and the correlation coefficient (R 2 ) was derived using Microsoft Excel to measure the association between C q value and input amount of synthetic miRNA. Statistical analysis was performed to compare (a) mean CTC counts and (b) ⌬C q values obtained from cancer patients and healthy donors. We used a nonparametric Mann-Whitney U-test (2tailed) analysis, as CTC counts did not exhibit normal distribution. Statistical significance was defined with ␣ ϭ 0.01. The relationship between the quantity of CTCs and tumor burden was analyzed with the use of Spearman correlation coefficients. Error bars represent standard error of the mean.
Results and Discussion
PAPER-BASED miRNA EXTRACTION FROM PLASMA
We devised a simple workflow for extracting miRNAs from both plasma and CTCs from blood, using an FTA paper-based approach to lyse cells and immobilize nucleic acids upon contact ( Fig. 1) .
To test the efficiency of the FTA Elute Card in miRNA retention, synthetic miRNAs miR-16, miR-93, and miR-141 were serially diluted to 10 2 to 10 8 copies (Fig. 2, A and B ). One microliter of synthetic miRNA was spotted onto either an FTA Elute Card or cellulose copier paper (Hewlett Packard), and allowed to dry for 1 h. After washing the papers with 70% ethanol, the miRNAs were eluted in DEPC water at 95°C for 30 min, and subjected to RT-qPCR. Pure synthetic miRNAs were used directly for RT-qPCR as positive control. The C q values obtained (Fig. 2B ) were plotted as a function of the number of copies of input synthetic miRNA. The plots for miRNA isolates from the FTA Elute Card displayed almost perfect linearity for all miRNAs tested ( Fig. 2A) . Plot results for the FTA Elute Card and positive control coincided almost perfectly, indicating minimal synthetic miRNA loss. In contrast, eluates from ordinary copier paper showed much higher C q values, indicating low retention of miRNAs ( Fig. 2B) . We further demonstrated that C q values of miRNAs adsorbed onto the FTA Elute Card stored at either room temperature (25°C) or Ϫ20°C were comparable to those of miRNAs adsorbed and extracted from FTA Elute Card on the same day (see online Supplemental Fig. 3 ), indicating feasibility of short-term storage of processed FTA Elute Cards loaded with miRNA.
To determine whether miRNAs recovered from plasma using the FTA Elute Card were proportionate to the input amounts, synthetic miR-141 was spiked into plasma obtained from healthy individuals to 10 4 -10 10 copies/L. The plot obtained showed almost perfect linearity (Fig. 3A) , while endogenous miRNA miR-451 showed similar C q values for all synthetic miRNA inputs tested. The relative proportions of synthetic miR-200c spiked into plasma were also preserved in the FTA eluates (Fig. 3, B and C) .
Additionally, we performed RT-qPCR on FTA eluates from 30-L samples of plasma from 12 breast cancer patients and 12 healthy individuals. RT-qPCR was initially performed for 30 miRNAs, but only 5 miRNAs showed marked up-regulation in cancer patients when compared to healthy volunteers. These miRNAs were further selected for clustering analysis using unsupervised hierarchical clustering ( Fig. 3D ) and principal component analysis (PCA) using 2 factors (see online Supplemental Fig. 4 ). Our results suggest that the FTA Elute Card-based method may be used for miRNA expression profiling in plasma, where changes in relative concentrations of different circulating miRNAs often indicate disease onset or progression (21 ) .
PAPER-BASED miRNA EXTRACTION FROM CTCs
To efficiently extract miRNAs from CTCs, we used the FTA Elute Card, which permits retention and subsequent elution of miRNAs, while the fibers within bind and trap PCR inhibitors such as hemoglobin from lysis of RBCs. To negate background miRNA readouts due to the blood cells, we adopted a digital-PCR-inspired protocol, in which captured cells are partitioned into smaller fractions to increase the CTC:WBC ratio ( Fig. 4) . As CTCs were present in much smaller numbers as compared to the contaminating WBCs and RBCs after microsieve filtration (18 ) , distribution of CTCs after microwell partitioning appeared to conform to the Poisson law of small numbers (22 ) , which resulted in each microwell receiving either zero or 1-10 CTCs, while the numbers of WBCs (100 -200) and RBCs (approximately 10000) remained relatively constant. Consequently, it was possible to identify and process microwells with no CTCs for the purpose of obtaining background miRNA readout due to contaminating blood cells. FTA eluates from CTC-containing and CTC-null wells were subjected to RT-qPCR separately. The difference in C q values was obtained for the 2 fractions (⌬C q ϭ C q of CTCcontaining fraction -C q of CTC-null fraction) and the calculated fold difference (2 ⌬Cq ) indicated miRNA expression from CTCs only.
We tested the ability of our protocol to detect 10 spiked-in MCF-7 cells in backgrounds of 1%, 50%, and 95% blood, and compared the outcome with that obtained using the Cell-to-C T kit (Thermo Fisher Scientific). Positive fold differences were registered for 95% blood background for all 4 miRNAs tested using the A simple, dichotomous workflow is designed for extracting and purifying miRNAs from both the highly abundant plasma and the rare CTCs from the blood of a cancer patient, using an FTA Elute paper-based approach to lyse cells and immobilize nucleic acids upon contact.
paper-based protocol, but not with the Cell-to-C T kit (Fig. 5a ). While both methods presented comparable C q values for blood-free MCF-7 cells (Fig. 5B ), the C q values derived using the Cell-to-C T kit were markedly higher than those obtained with our protocol for all background blood concentrations tested. These results demonstrate the importance of the simple purification step afforded by the FTA Elute Card, which is easily applied to the microwells to absorb minute volumes of less than 1 L.
Using various cell lines (MCF-7, HT-29, DU145) spiked into healthy donor's blood to simulate the CTC enrichment process using the microsieve, we observed increases in fold differences obtained with increasing CTC numbers (Fig. 5C ). CTC-specific miRNA signals (A) PCR amplification curves for increasing amounts of synthetic miR-141 spiked into healthy donor's plasma and extracted using paper-based approach. Inset: standard curve depicting correlation between miRNA input and C q values. NTC, nontemplate control. Endogenous miRNA miR-451 was detected at similar C q values for all synthetic miRNA inputs tested. C q value of endogenous miR-141 was also detected prior to spiking of synthetic miRNAs. (B, C), PCR amplification curves for healthy donor's plasma spiked with 10 10 miR-141 versus 10 8 miR-200C (b), or 10 8 miR-141 versus 10 10 miR-200C (C), and extracted using paper-based approach. Endogenous miR-21 was detected at similar C q values for both (B) and (C). C q value of endogenous miR-141 and miR-200c was also detected prior to spiking of synthetic miRNAs. (D), Unsupervised hierarchical clustering heat map of expression profiles for paper-extracted miRNAs from plasma of 12 cancer patients and 12 healthy controls. with fold difference close to 100 were derived from as few as 3 cells (Fig. 5C ), indicating that individual cancer cells may harbor very high transcript levels of specific miRNA(s). Thus, while our method may not be efficient in picking up low copy numbers (Ͻ10 2 copies) of miRNAs (Fig. 2) , it is useful in detecting miRNAs that are expressed at high levels in CTCs that may be of clinical relevance.
miRNA EXPRESSION PROFILES FROM CTCs FROM CANCER
PATIENTS
We profiled the miRNA expression from CTCs from 21 breast or colorectal cancer patients, with 20 healthy controls. Using our previously described microsieve method for CTC isolation (18 ) , CTC counts were significantly higher in cancer patients (mean ϭ 23. Table 1 ). As ⌬C q values exceeding 1.20 were only observed in CTCs from cancer patients but not healthy controls (Fig. 6B) , the threshold for miRNA detection was set at fold difference of 2.30 (corresponding to ⌬C q ϭ 1.2).
We studied the expression profile for selected miRNAs in the 21 cancer patients and 3 healthy controls. Cancer patients had higher CTC counts than healthy controls (Fig. 6C ). Twelve patients showed significant expression of miRNAs in Panel 1 (Fig. 6D) , which included miR-200c, miR-141, miR-93, miR-21, and miR-16, known to play significant roles in metastasis. The patients with no readouts for Panel 1 were further analyzed with Panel 2, which included miRNAs involved in chemoresistance, such as miR-221/-222 (tamoxifen) (23 ), miR-328 (mitoxantrone) (24 ) , miR-28/miR-106a/miR-206 (doxorubicin) (25 ) , miR-125 (paclitaxel) (26 ) , and miR-194 (trastuzumab) (27 ) . Fold differences CTC-positive and CTC-negative microwells were identified by fluorescence microscopy (BX61, Olympus), and the miRNAs were extracted from them using the FTA Elute Card. RT-qPCR was subsequently performed to detect the miRNAs expressed and fold difference was calculated as described in the Materials and Methods. Insets: (Top) WBCs (green/blue) and CTCs (blue, indicated by white arrows) in CTC-containing (left) or CTC-null (right) microwells. Scale bar, 100 μm. (Bottom) RBCs in microwells. Scale bar, 300 μm. (A), RT-qPCR detection of FTA-extracted miRNAs from 10 MCF-7 cancer cells spiked into 1%-95% blood dilutions. miRNAs were extracted using FTA Elute Card (GE Healthcare Life Sciences) or Cell-to-C T kit (Thermo Fisher Scientific). ΔC q values were derived from the difference in C q values between cancer-cell-positive and -negative microwells. (B), Correlation plot between C q values from FTA Elute Card-extracted miRNAs and Cell-to-C T kit-extracted miRNAs from MCF-7 cells. (C), 3-100 cells from 3 different human cell lines of different organ origins (breast MCF-7, colorectal HT-29 and prostate DU145) were spiked into blood from a healthy control, and passed through the microsieve (CellSievo). CTCs and WBCs trapped on the microsieve were eluted, and partitioned as depicted in Fig. 4 . Error bars represent mean (SD) of 3 experiments. Ͼ2.30 were obtained for at least 1 miRNA from Panel 2 for all 7 patients tested but not from healthy controls (Fig. 6E ). Unfortunately, due to limited patient CTC sample that we could harvest, we were unable to perform technical validation of our protocol using these samples. Also, further validation of these miRNA identified are required in larger cohort studies.
To determine the feasibility of our paper-based method for miRNA biomarker discovery from CTCs, a high-throughput qPCR array was used to uncover miRNAs highly expressed in CTCs from 1 breast cancer patient with 95 CTCs (see online Supplemental Fig. 5A ). Of the 377 miRNAs interrogated, 26 miRNAs had positive ⌬C q values (see online Supplemental Fig. 5B ). In silico prediction and literature search revealed these miRNAs to be involved in multiple signaling pathways regulating tumorigenesis (see online Supplemental Fig.  5C ). Although there have been reports of detection of few miRNAs in CTCs using real-time PCR (28 ) or in situ hybridization (29 ) , apart from a published study by Sieuwerts and colleagues (9 ) , there have been no further reports of comprehensive miRNA expression profiling from CTCs. In Sieuwerts et al's study, to overcome the problem of molecular signals from contaminating blood cells, only 43 miRNAs, which were at least 10 times more abundant in primary breast tumor cells than in blood cells, were selected out of 446 miRNAs for final testing (9 ) . The disadvantage of this approach is that miRNAs that are highly expressed in blood cells cannot be included in the CTC-associated miRNA expression profiling panel, notwithstanding their established roles in tumorigenesis, e.g., miR-21 (30 ) and miR-93 (31 ) and/or chemoresistance. This limitation is circumvented by our digital PCR-inspired partitioning approach. miR-21, miR-93, miR-221, miR-222, and miR-194, all excluded from Sieuwerts et al.'s study due to low breast tumor: blood cells signal ratios (9 ) , were shown to be highly expressed in cancer patients (Fig. 6 , D and E), indicating the feasibility of studying a wide range of miRNA in blood cells-contaminated CTC preparations.
Longitudinal CTC-specific miRNA expression profiling of 1 breast cancer patient was performed over the course of neoadjuvant chemotherapy (see online Supplemental Fig. 6A ). Different miRNAs expression profiles were observed before and after chemotherapy with decrease in miR-28 -5p and miR-221, and emergence of miR-106b postchemotherapy (see online Supplemental  Fig. 6B ). Again, as a result of limited patient CTC sample, we were unable to perform technical validation of our protocol using these samples. miR-106b has been shown to bypass doxorubicin-induced senescence and increase in cancer cell motility and invasion (32 ) , hence the emergence of miR-106b may indicate doxorubicin resistance. This association is highly hypothetical and further validation of the association of miR-106b with doxoru-bicin resistance in larger cohort studies is required. Molecular characterization of CTCs, such as detection of HER2 amplification (33, 34 ) and EGFR mutations (35 ) can be useful markers of acquired drug resistance and guide therapeutic decisions. miRNAs have been implicated in tumorigenesis (3, 4 ) , epithelial-to-mesenchymal transition (EMT) (36, 37 ) , and drug resistance (23) (24) (25) (26) (27) . Our paper-based cell partitioning method can track changes in CTC-specific miRNA expression which may provide insights into the molecular mechanisms of metastasis, EMT, and drug resistance.
Conclusions
Combining the use of the FTA Elute Card with a digital PCR-inspired partitioning approach, we developed a simple and parsimonious workflow for extracting miRNAs from both plasma and CTCs from blood. Using this method, background miRNA expression was excluded from contaminating blood cells, and CTCspecific miRNA expression profiles were derived from breast and colorectal cancer patients. Our paper-based approach reduces cost, while maximizing the molecular information that can be recovered from limited patient samples contaminated with blood-derived PCR inhibitors.
